Health Care & Life Sciences » Biotechnology | Fate Therapeutics Inc.

Fate Therapeutics Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
971.00
-
2,431.00
4,402.00
4,106.00
4,740
Cost of Goods Sold (COGS) incl. D&A
-
496.00
-
-
-
-
Gross Income
-
496.00
-
-
-
-
SG&A Expense
18,075.00
24,408.00
29,526.00
35,484.00
45,260.00
70,628
EBIT
17,675.00
24,904.00
27,782.00
-
42,125.00
67,092
Unusual Expense
2,429.00
432.00
-
-
118.00
-
Interest Expense
796.00
549.00
2,220.00
1,637.00
1,268.00
1,696
Pretax Income
20,894.00
25,883.00
29,992.00
33,462.00
42,952.00
66,598
Consolidated Net Income
20,894.00
25,883.00
29,992.00
33,462.00
42,952.00
66,598
Net Income
20,894.00
25,883.00
29,992.00
33,462.00
42,952.00
66,598
Net Income After Extraordinaries
20,894.00
25,883.00
29,992.00
33,462.00
42,952.00
66,598
Net Income Available to Common
20,894.00
25,883.00
29,992.00
33,462.00
42,952.00
66,598
EPS (Basic)
3.54
1.27
1.18
1.05
1.02
1.19
Basic Shares Outstanding
5,896.20
20,451.80
25,484.30
31,754.10
41,982.20
56,195.70
EPS (Diluted)
3.54
1.27
1.18
1.05
1.02
1.19
Diluted Shares Outstanding
5,896.20
20,451.80
25,484.30
31,754.10
41,982.20
56,195.70
EBITDA
17,104.00
24,408.00
27,095.00
31,082.00
41,154.00
65,888
Non-Operating Interest Income
6.00
2.00
10.00
138.00
559.00
2,190

About Fate Therapeutics

View Profile
Address
3535 General Atomics Court
San Diego California 92121
United States
Employees -
Website http://www.fatetherapeutics.com
Updated 07/08/2019
Fate Therapeutics, Inc. is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. It programmed cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system. The company products include ProHema, ProTmune, Adaptive NK, iPSC-derived NK, Programmed CD34 and T cell therapy.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.